ABBVIE

AbbVie announces positive Phase 3 TEMPO-1 trial results for tavapadon, a D1/D5 dopamine receptor partial agonist, as a monotherapy for early Parkinson's disease, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26.

AbbVie's RINVOQ (upadacitinib) showed positive results in Phase III trials for moderate-to-severe atopic dermatitis, with higher doses achieving near-complete skin clearance in head and neck regions, improving quality of life, and minimal disease activity at week 16 compared to placebo.

AI-powered collaborations drive billion-dollar deals, accelerating antibody design, biopharmaceuticals, and next-gen biologics development.

Tavapadon, a dopamine agonist, met its primary endpoint in the TEMPO-1 trial for Parkinson’s disease, showing significant reduction in MDS-UPDRS scores. This follows positive results from the TEMPO-3 trial, with the final TEMPO-2 trial expected to conclude this year. Tavapadon aims to offer effective treatment with minimal side effects.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

IBD, including Crohn's disease and ulcerative colitis, lacks reliable predictors for treatment response. This Research Topic aims to identify and validate novel biomarkers to optimize personalized therapy, focusing on genetic, microbial, transcriptomic, and immunologic data.

AbbVie announces positive Phase 3 TEMPO-1 trial results for tavapadon, a D1/D5 dopamine receptor partial agonist, as a monotherapy for early Parkinson's disease, showing significant reduction in MDS-UPDRS Parts II and III scores compared to placebo.

RINVOQ® (upadacitinib) demonstrated efficacy in moderate-to-severe atopic dermatitis patients with varying head and neck involvement, achieving skin clearance, itch resolution, and improved quality of life at 16 weeks.

The EMA's CHMP recommended marketing authorization for mirvetuximab soravtansine (Elahere; AbbVie) for FRα+, platinum-resistant ovarian cancer, based on MIRASOL trial results showing improved PFS, ORR, and OS compared to chemotherapy. The European Commission is expected to decide on this indication in 2024.